Report Description Table of Contents How Are Venous Disorders, Minimally Invasive Procedures, and Advanced Foam Technologies Shaping the Global Sclerotherapy Market? – (Updated On: 13th-Oct-2026) The Global Sclerotherapy Market was estimated at USD 1.30 billion in 2025 and is projected to reach USD 2.01 billion by 2032, expanding at a CAGR of 6.40% during 2026–2032, according to Strategic Market Research. Sclerotherapy Market refers to the global market for minimally invasive treatments that use specialized liquid or foam injections to close abnormal veins, primarily varicose veins and spider veins. Varicose veins and spider veins represent a substantial clinical population for sclerotherapy worldwide. Germany's Bonn Vein Study, involving 3,072 adults, identified 59.0% with telangiectatic or reticular veins (CEAP C1) and 14.3% with varicose veins (CEAP C2), representing approximately 1,812 and 439 participants, respectively. In the United States, the Society for Vascular Surgery estimates that up to 40 million Americans have varicose veins, while the Society for Cardiovascular Angiography & Interventions (SCAI) reports more than 25 million adults affected by chronic venous disease, establishing a substantial population requiring venous assessment and, where clinically appropriate, treatment. Actual sclerotherapy utilization provides a more direct measure of treatment activity. The American Society of Plastic Surgeons recorded an estimated 516,883 cosmetic sclerotherapy procedures in the United States during 2024, Sclerotherapy remains an established outpatient option for spider veins and selected symptomatic varicose veins, with clinical eligibility, disease severity, and treatment preferences influencing procedure volumes. The treatment landscape is centered on liquid sclerosants for spider veins and smaller reticular veins, while ultrasound-guided foam sclerotherapy is used for selected larger varicose veins and incompetent superficial venous systems. Major treatment agents include polidocanol, sodium tetradecyl sulfate, and Boston Scientific's Varithena (polidocanol injectable foam). Clinical studies of Varithena, including the VANISH-2 trial, have demonstrated improvements in vein closure, symptoms, and appearance among appropriately selected patients. The increasing use of specialized foam formulations and ultrasound-guided procedures is influencing sclerosant selection, treatment practices, and commercial opportunities across outpatient vein clinics and vascular treatment centers. Overall, the Sclerotherapy Market is supported by a substantial population affected by varicose and spider veins, established outpatient procedure activity, and clinically validated liquid and foam sclerosant treatments. Pharmaceutical consumption and procedure-related spending depend on the number of eligible patients receiving injections, the choice of liquid or foam formulations, treatment-session frequency, and reimbursement coverage. Ultrasound-guided foam procedures, specialized sclerosant formulations, and medically indicated venous interventions remain important areas shaping the market's commercial opportunities. Which Segments Lead the Sclerotherapy Market, and Where Are the Fastest-Growing Opportunities Emerging? By Treatment Type: Foam Leadership and Ultrasound-Guided Growth Leading Segment – Foam Sclerotherapy Foam sclerotherapy is a widely adopted treatment for larger, bulging varicose veins, using a foamed chemical sclerosant to close affected veins while potentially reducing the number of treatment sessions compared with conventional liquid sclerotherapy. Within the Sclerotherapy Market, foam sclerotherapy led the treatment-type category with an estimated 38% market share, equivalent to USD 494 million in 2025, and is projected to register a CAGR of 5.40% during 2026–2032, supported by its minimally invasive approach, ultrasound-guided precision, and suitability for treating larger superficial veins. Fastest-Growing Segment – Ultrasound-Guided Foam Sclerotherapy (UGFS) Ultrasound-Guided Foam Sclerotherapy (UGFS) is a minimally invasive procedure that uses real-time ultrasound imaging to deliver medicated microfoam into diseased, tortuous, or deep-seated veins, improving treatment precision for complex venous conditions. Within the global sclerotherapy market, UGFS accounted for an estimated 28% market share, valued at USD 364 million in 2025, and is projected to register the fastest CAGR of 8.08% during 2026–2032, supported by its growing clinical adoption for varicose veins, recurrent venous insufficiency, and anatomically challenging vein disorders. By Sclerosing Agent: Polidocanol Leads in Share and Growth Leading and Fastest-Growing Segment – Polidocanol Polidocanol held the largest share of the global sclerotherapy market at approximately 48% in 2025, valued at USD 624 million, and is projected to maintain the fastest growth rate, registering a CAGR of 7.06% during 2026–2032. As a widely used detergent-based sclerosing agent, polidocanol disrupts vascular endothelial cell membranes, causing localized thrombosis and subsequent fibrosis that closes abnormal blood vessels. Its established clinical use in treating varicose veins, spider veins, and venous malformations strengthens its position across minimally invasive vascular procedures. By Application: Varicose Veins Lead as Venous Malformations Expand Leading Segment – Varicose Veins Varicose veins accounted for the largest application share of the global sclerotherapy market, representing approximately 61% in 2025, equivalent to USD 793 million, with a projected CAGR of 6.00% during 2026–2032. Varicose veins develop when weakened venous valves cause blood to accumulate in superficial veins, resulting in venous reflux, swelling, and impaired circulation. Sclerotherapy addresses affected veins through targeted injection treatments that close abnormal vessels and redirect blood flow toward healthier veins, supporting its established role in managing symptomatic varicose veins. Fastest-Growing Segment – Venous Malformations Venous malformations accounted for an estimated 6% of the global sclerotherapy market, valued at USD 78 million in 2025, and are projected to register the fastest CAGR of 10.25% during 2026–2032. Sclerotherapy remains the preferred first-line treatment for low-flow venous malformations, which involve congenital clusters of abnormally dilated veins. Its ability to reduce lesion size, relieve pain, control swelling, and improve functional outcomes supports increasing clinical adoption, particularly among patients with symptomatic malformations requiring minimally invasive treatment rather than extensive surgical intervention. By End User: Specialty Vein Clinics Lead as Surgical Centers Expand Leading Segment – Specialty Vein Clinics Specialty vein clinics accounted for the largest estimated share of 54% in the global sclerotherapy market, valued at USD 702 million in 2025, and are projected to expand at a CAGR of 5.90% during 2026–2032. Their leading position is supported by specialized vascular expertise, comprehensive venous diagnosis, ultrasound-guided vein mapping, and precise administration of sclerosing agents. Dedicated treatment facilities also offer minimally invasive procedures, personalized treatment planning, and follow-up care, supporting effective management of spider veins and varicose veins with improved clinical outcomes. Fastest-Growing Segment – Ambulatory Surgical Centers Ambulatory Surgical Centers accounted for an estimated 12% of the Sclerotherapy Market, representing USD 156 million in 2025, and are projected to record the fastest CAGR of 7.89% during 2026–2032. Sclerotherapy is primarily a minimally invasive, office-based procedure that typically does not require an Ambulatory Surgical Center. However, ASCs remain relevant for selected patients requiring specialized vascular care, additional procedural support, or treatment of complex venous conditions. Their growth reflects increasing utilization of outpatient vascular procedures in specialized surgical settings. By Geography: North America Leads as Asia-Pacific Accelerates Leading Region – North America North America maintained its leading position in the global Sclerotherapy Market, accounting for approximately 36% of the market share, valued at USD 468 million in 2025, with a projected CAGR of 5.70% during 2026–2032. Sclerotherapy is well established across the region's healthcare system as a standard treatment for varicose veins, spider veins, and selected peripheral venous disorders. The widespread presence of specialized vascular clinics, established reimbursement pathways for medically necessary procedures, and increasing adoption of minimally invasive venous treatments reinforce North America's market leadership. Fastest-Growing Region – Asia-Pacific Asia-Pacific accounted for an estimated 25% of the global sclerotherapy market, valued at USD 325 million in 2025, and is projected to register the fastest regional CAGR of 8.14% during 2026–2032. Sclerotherapy adoption is expanding across China, Japan, India, and South Korea as patients increasingly seek minimally invasive treatment for varicose and spider veins. Growing availability of specialized vein clinics, greater awareness of venous disorders, and improving access to outpatient vascular procedures are strengthening the region’s position in non-surgical vein treatment. Which Companies Are Leading the Sclerotherapy Market Through Advanced Foam Technologies and Specialized Venous Treatments? Boston Scientific – Advanced Polidocanol Microfoam Technology Boston Scientific is a prominent supplier of minimally invasive venous treatment technologies through its Varithena 1% polidocanol injectable microfoam, an FDA-approved treatment for incompetent great saphenous veins and associated varicosities. Its patented Microfoam UDSS technology produces a controlled oxygen–carbon dioxide foam containing less than 0.8% nitrogen, enabling consistent contact with affected vein walls. The company's VANISH-1 clinical trial involving 279 patients reported an 80.4% duplex ultrasound response rate among patients receiving Varithena 1%. The treatment's clinical evidence and standardized formulation strengthen Boston Scientific's competitive position in non-thermal venous interventions. Kreussler Pharma – Polidocanol Formulations and International Sclerotherapy Distribution Kreussler Pharma maintains an established position in pharmaceutical sclerotherapy through Aethoxysklerol (polidocanol), which is used in liquid and foam treatment of varicose veins and smaller superficial veins. Its formulations support different treatment requirements, including outpatient vascular procedures and specialized venous interventions. Aethoxysklerol is registered in more than 30 countries, including Germany, France, Japan, and China, demonstrating the company's international regulatory and distribution reach. Kreussler also distributes Fibrovein (sodium tetradecyl sulfate) in France, expanding its commercial coverage across established sclerosing-agent categories. Other Important Companies and Their Market Roles: Methapharm: Distributes FDA-approved Asclera 0.5% and 1% polidocanol injections for spider and reticular veins and ScleroSafe mechanical-chemical vein treatment technology in the United States. STD Pharmaceutical Products: Supplies Fibrovein sodium tetradecyl sulfate, supporting liquid and foam sclerotherapy for varicose veins through pharmaceutical manufacturing and distribution. VVT Medical: Develops ScleroSafe, combining mechanical disruption of the venous lining with chemical ablation for minimally invasive varicose vein treatment. Analyst Commentary: How Will Advanced Foam and Outpatient Venous Care Shape Market Expansion? The sclerotherapy market is shifting toward more precise, minimally invasive venous treatments, with ultrasound-guided foam sclerotherapy and standardized polidocanol formulations creating important opportunities. The strongest commercial potential lies in treating symptomatic varicose veins, expanding image-guided interventions for complex venous disorders, and increasing outpatient procedure accessibility. Greater clinical adoption will depend on treatment effectiveness, reimbursement coverage, and competition from endovenous ablation technologies. Advanced foam formulations and specialized vascular care are expected to shape future treatment preferences and market expansion. Sclerotherapy Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.30 Billion Revenue Forecast in 2032 USD 2.01 Billion Overall Growth Rate CAGR of 6.40% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Sclerosing Agent, By Application, By End User, By Geography By Treatment Type Foam Sclerotherapy, Liquid Sclerotherapy, Ultrasound-Guided Foam Sclerotherapy (UGFS) By Sclerosing Agent Polidocanol, Sodium Tetradecyl Sulfate (STS), Hypertonic Saline By Application Varicose Veins, Spider Veins, Reticular Veins, Venous Malformations By End User Specialty Vein Clinics, Hospitals, Ambulatory Surgical Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers High prevalence of varicose and spider veins, established outpatient sclerotherapy procedures, growing adoption of foam and ultrasound-guided foam sclerotherapy, increasing use of polidocanol formulations, demand for minimally invasive venous treatment, expansion of specialty vein clinics, growing use of image-guided procedures for complex venous conditions, and increasing access to outpatient vascular care Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are encouraging wider adoption across the market? A1. Adoption is being supported by the high prevalence of varicose and spider veins, established outpatient treatment volumes, and growing preference for minimally invasive procedures. Wider availability of ultrasound-guided techniques is also expanding patient eligibility. Q2. What are the key trends shaping the industry? A2. The industry is moving toward ultrasound-guided foam procedures, standardized polidocanol formulations, and specialized outpatient venous care. Image-guided treatment is also gaining importance for more complex vein conditions. Q3. Why is ultrasound-guided foam treatment gaining importance in the market? A3. Ultrasound guidance helps physicians deliver foam precisely into deeper or tortuous veins. This improves treatment accuracy and is supporting greater use in recurrent venous insufficiency and anatomically complex cases. Q4. Which applications are creating the strongest opportunities in the industry? A4. Varicose veins remain the largest application, while venous malformations are projected to grow faster. Their treatment often requires specialized image-guided procedures that can reduce pain and lesion size without extensive surgery. Q5. How are outpatient treatment settings influencing the market? A5. Specialty vein clinics and selected ambulatory centers are expanding access to minimally invasive procedures. Their focus on shorter treatments, vascular expertise, and follow-up care supports greater procedure volumes outside large hospitals. Q6. Which region is expected to record the fastest growth in the industry? A6. Asia-Pacific is projected to record the fastest regional CAGR of about 8.14% during 2026–2032. Growth is supported by expanding vein clinics, greater awareness of venous disorders, and wider access to outpatient treatment across China, Japan, India, and South Korea. Sources: American Society of Plastic Surgeons (ASPS) – 516,883 Cosmetic Sclerotherapy Procedures Reported in the United States in 2024 ASPS – 2024 Plastic Surgery Procedural Statistics and Sclerotherapy Activity Society for Cardiovascular Angiography & Interventions (SCAI) – More Than 25 Million U.S. Adults Affected by Chronic Venous Disease; 2025 Guidelines Address Sclerotherapy and Venous Ablation SCAI – 2025 Clinical Practice Guidelines for Chronic Venous Disease NIH PubMed – Germany's Bonn Vein Study Evaluated 3,072 Adults; 59.0% Had Telangiectatic or Reticular Veins and 14.3% Had Varicose Veins NIH PubMed – Bonn Vein Study: Prevalence of Chronic Venous Disorders U.S. Centers for Medicare & Medicaid Services (CMS) – April 2026 Coverage Policy Recognizes Polidocanol Microfoam for Medically Necessary Saphenous Vein Treatment Subject to Eligibility Criteria CMS – Medicare Coverage Determination for Varicose Vein Treatments (L33575) U.S. FDA – Varithena 1% Polidocanol Injectable Foam Approved for Great Saphenous Vein Insufficiency; VANISH-1 Trial Reported 80.4% Duplex Ultrasound Response With the 1% Formulation FDA – Varithena Prescribing Information and Clinical Trial Efficacy Results Boston Scientific – VANISH-1 Clinical Trial Enrolled 279 Patients; Varithena 1% Achieved an 80.4% Duplex Ultrasound Response Rate at Eight Weeks Boston Scientific – Varithena VANISH-1 Clinical Trial Results and Treatment Effectiveness Kreussler Pharma – Aethoxysklerol (Polidocanol) Registered in More Than 30 Countries, Including Germany, France, Japan, and China Kreussler – Aethoxysklerol International Product Registrations and Distribution Network Kreussler Pharma and STD Pharmaceutical Products – Strategic Partnership Established in December 2023 for Global Production, Marketing, and Distribution of Fibrovein Sclerotherapy Products Kreussler – Strategic Partnership for Fibrovein Manufacturing and International Commercialization Methapharm – FDA-Approved Asclera Polidocanol Injections Available in 0.5% and 1% Concentrations for Spider Veins and Reticular Veins; Initial U.S. Approval in 2010 U.S. National Library of Medicine – Methapharm Asclera FDA Prescribing Information Table of Contents - Global Sclerotherapy Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Sclerosing Agent, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Sclerosing Agent, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Sclerosing Agent, Application, and End User Investment Opportunities in the Sclerotherapy Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Foam Sclerotherapy, Ultrasound-Guided Foam Sclerotherapy, Polidocanol Formulations, Specialty Vein Clinics, and Minimally Invasive Venous Treatments Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Sclerotherapy in Varicose Veins, Spider Veins, Reticular Veins, and Venous Malformations Treatment Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approval, Clinical Evidence, and Reimbursement Factors Role of Foam Sclerotherapy, Liquid Sclerotherapy, and Ultrasound-Guided Foam Sclerotherapy in Market Expansion Patient Selection, Minimally Invasive Treatment, and Outpatient Venous Care Trends Global Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Foam Sclerotherapy Liquid Sclerotherapy Ultrasound-Guided Foam Sclerotherapy (UGFS) Market Analysis by Sclerosing Agent: Polidocanol Sodium Tetradecyl Sulfate (STS) Hypertonic Saline Market Analysis by Application: Varicose Veins Spider Veins Reticular Veins Venous Malformations Market Analysis by End User: Specialty Vein Clinics Hospitals Ambulatory Surgical Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Sclerosing Agent, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Sclerosing Agent, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Sclerosing Agent, Application, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Sclerosing Agent, Application, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Sclerotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Sclerosing Agent, Application, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Boston Scientific Corporation Kreussler Pharma Methapharm STD Pharmaceutical Products VVT Medical Medtronic plc Merz Pharma GmbH & Co. KGaA Baxter International Inc. AngioDynamics, Inc. Biolitec AG Competitive Landscape and Strategic Insights Benchmarking Based on Sclerosant Formulations, Clinical Evidence, Regulatory Approvals, Distribution Networks, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Polidocanol and Sodium Tetradecyl Sulfate Formulation Positioning Foam Sclerotherapy and Minimally Invasive Venous Treatment Competitiveness Ultrasound-Guided Foam Sclerotherapy and Outpatient Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Sclerosing Agent, Application, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance and Treatment Access Analysis Technology Adoption Trends Across Foam Sclerotherapy, Liquid Sclerotherapy, and Ultrasound-Guided Foam Sclerotherapy List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Sclerosing Agent, Application, and End User (2025 vs. 2032) Global Sclerotherapy Ecosystem and Value Chain Analysis